

Capital Raise Update

Sydney, Australia – 15 November 2023: Cannabis focused drug development and product innovation company Bod Science Limited (“Bod” or “the Company”) (ASX: BOD) refers to its capital raising announcement dated 8 November, 2023 (**Placement**). Pursuant to that announcement, shares were intended to be issued under Tranche One of the Placement on 14 November 2023.

Bod advises that settlement of Tranche One of the Placement has been delayed due to an administrative delay in the transfer of funds from outside Australia.

Bod now expects that settlement of the shares to be issued under Tranche One of the Placement will occur on or around Monday, 20 November 2023 and will advise the market as soon as settlement has occurred.

This announcement has been approved by the Chairman of Bod Science Limited.

-ENDS-

About Bod Science:

Bod Science (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers.

The company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018

Amalie Schreurs
White Noise Communications
amalie@whitenoisecomms.com
+61 431 636 033